Osteopontin: an emerging therapeutic target in uraemic vascular disease
- PMID: 23612585
- PMCID: PMC3656615
- DOI: 10.1093/cvr/cvt098
Osteopontin: an emerging therapeutic target in uraemic vascular disease
Figures
Comment on
-
Osteopontin deficiency dampens the pro-atherogenic effect of uraemia.Cardiovasc Res. 2013 Jun 1;98(3):352-9. doi: 10.1093/cvr/cvt049. Epub 2013 Mar 1. Cardiovasc Res. 2013. PMID: 23455547
References
-
- Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2011. U.S. Renal Data System, USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States.
-
- London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003;18:1731–1740. - PubMed
-
- Moe SM, Chen NX. Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol. 2008;19:213–216. - PubMed
-
- Baber U, de Lemos JA, Khera A, McGuire DK, Omland T, Toto RD, et al. Non-traditional risk factors predict coronary calcification in chronic kidney disease in a population-based cohort. Kidney Int. 2008;73:615–621. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
